392 related articles for article (PubMed ID: 37371463)
1. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
2. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
3. Loss of MTA2-mediated downregulation of PTK7 inhibits hepatocellular carcinoma metastasis progression by modulating the FAK-MMP7 axis.
Hu HM; Lee HL; Liu CJ; Hsieh YH; Chen YS; Hsueh KC
Environ Toxicol; 2024 Apr; 39(4):1897-1908. PubMed ID: 38050825
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
5. MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway.
Guan C; Chang Z; Gu X; Liu R
Biochem Biophys Res Commun; 2019 Jul; 515(1):112-118. PubMed ID: 31128910
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation.
Lee H; Ryu SH; Hong SS; Seo DD; Min HJ; Jang MK; Kwon HJ; Yu E; Chung YH; Kim KW
J Gastroenterol Hepatol; 2009 Aug; 24(8):1445-50. PubMed ID: 19702911
[TBL] [Abstract][Full Text] [Related]
7. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
8. Expression of MTA2 and Ki-67 in hepatocellular carcinoma and their correlation with prognosis.
Shi W; Hu J; Zhu S; Shen X; Zhang X; Yang C; Gao H; Zhang H
Int J Clin Exp Pathol; 2015; 8(10):13083-9. PubMed ID: 26722504
[TBL] [Abstract][Full Text] [Related]
9. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract][Full Text] [Related]
12. SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells.
Yang Y; Qiu R; Zhao S; Shen L; Tang B; Weng Q; Xu Z; Zheng L; Chen W; Shu G; Wang Y; Zhao Z; Chen M; Ji J
BMC Biol; 2022 Dec; 20(1):294. PubMed ID: 36575438
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
14. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.
Si W; Liu X; Wei R; Zhang Y; Zhao Y; Cui L; Hong T
Cell Death Dis; 2019 Feb; 10(3):206. PubMed ID: 30814496
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
16. An integrative analysis reveals the prognostic value and potential functions of MTMR2 in hepatocellular carcinoma.
Yao Y; Lai J; Yang Y; Wang G; Lv J
Sci Rep; 2023 Oct; 13(1):18701. PubMed ID: 37907649
[TBL] [Abstract][Full Text] [Related]
17. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
18. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
Chen D; Zhou W; Chen J; Wang J
Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
[TBL] [Abstract][Full Text] [Related]
19. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
20. Deep dissection of stemness-related hierarchies in hepatocellular carcinoma.
Liang R; Hong W; Zhang Y; Ma D; Li J; Shi Y; Luo Q; Du S; Song G
J Transl Med; 2023 Sep; 21(1):631. PubMed ID: 37717019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
